Dr Maggie Lucy Kalev
MBChB, PhD, FRCPA
I am a medical academic trained in New Zealand (since 1995), South Africa (1991-1994) and Poland (prior to 1991). My medical specialisation is in laboratory haematology with a Fellowship of the Royal College of Pathologists of Australasia gained in 2000. I first joined the University of Auckland in 1999 when I undertook a PhD into the mechanisms of leukaemogenesis, completing it in 2003. I then continued in a post-doctoral position until 2008 learning genetic modification and gene therapy approaches. In 2009, I was appointed to a position of Senior Lecturer in Cancer Biology and returned to haematological science. My current University position includes 0.2 FTE as a Consultant Haematopathologist at Auckland City Hospital, where my expertise is in blood cancer diagnosis. Since my appointment at the University of Auckland in 2009, I have established and now lead an independent research group that focuses on blood and cancer biology.
- 2003 PhD in Molecular Medicine, University of Auckland
- 2000 FRCPA in Haematology, Royal College of Pathologists of Australasia
- 1990 MBChB Medicine and Surgery, Pomeranian Medical School (Pomorska Akademia Medyczna), Szczecin, Poland
Professional positions held:
- 2009-present Senior Lecturer, Head of Research Group, Department of Molecular Medicine and Pathology, University of Auckland (0.8 FTE)
- 2005-present Consultant Haematologist, Department of Pathology and Laboratory Medicine, Haematology Laboratory, Auckland City Hospital (0.2 FTE)
- 2000-2008 Consultant Haematologist, contract sessions, Diagnostic MedLab, Auckland
- 2004-2008 Research Fellow, Functional Genomics and Translational Neuroscience Laboratory, University of Auckland
- 1999-2003 PhD Fellowship, Developmental Genetics and Leukaemia Laboratory, University of Auckland
- 1996-1998 Registrar in Haematology, Auckland City and Middlemore Hospitals, New Zealand Blood Service
- 1993-1994 Registrar in Haematology (Haematology Laboratory, Bone Marrow Transplant Unit, Haematology Ward and Outpatients), Groote Schuur Hospital, Cape Town, South Africa
- 1991-1994 Senior House Officer in Haematology and Cardiology (Bone Marrow Transplant Unit, Haematology Outpatients, Intensive Coronary Care Unit and Haematology Laboratory), Groote Schuur Hospital, Cape Town, South Africa
- 1990-1991 Resident in Cardiology, Intensive Care Unit, Collegium Medicum of the Jagiellonian University, Cracow, Poland
- 1989-1990 Intern, Military Hospital, Cracow, Poland
Research | Current
Research group: Blood and Cancer Biology Laboratory.
- Laboratory and molecular haematology
- Leukaemia and cancer biology
- Megakaryocytes and platelets
- Calcium signalling
- Experimental therapeutic targets
- Gene editing
1. Can we find novel ways to regulate platelet production?
Platelets are critical for normal blood clotting and tissue repair. Platelets are produced by precursor cells called megakaryocytes located in the adult bone marrow. The process of platelet production remains incompletely understood. This project examines mechanisms that regulate megakaryocyte maturation and platelet production. We work with the bioengineering team to develop and test a bioreactor device in which to examine the dynamics or proplatelet formation and platelet release. Human and mouse haematopoietic precursors are tested in culture, and a transgenic mouse model is used to examine aspects of platelet production in vivo. Our focus is on signals that trigger proplatelet formation and platelet release into bone marrow blood vessels. Our overriding aim is to identify novel ways to correct abnormal platelet counts in patients, and to help enhance platelet production ex vivo for transfusion purposes and tissue repair.
2. What drives megakaryocytic cancers?
Megakaryocytic cancers include acute megakaryoblastic leukaemia and certain chronic myeloproliferative neoplasms (essential thrombocytosis and primary myelofibrosis). The pathogenesis of these cancers remains incompletely elucidated and patients outcomes are often poor. This research is a part of the MegBio project https://megbio.blogs.auckland.ac.nz/ developed by our team. We examine patient samples using approaches that include genome and transcriptome testing to uncover novel pathogenic mechanisms that drive disease. Our overriding aim is to identify new targets for the treatment of patients with megakaryocytic cancers.
Current grants as PI:
2021-2023 Cancer Research Trust; project grant: Unfolded protein response in myeloproliferative neoplasms; $79,715.
2019-2022 Auckland Medical Research Foundation; project grant: Unfolded protein response in myeloproliferative neoplasms; $159,999.
2019-2022 Bone Marrow Cancer Trust (Christchurch); project grant: The role of mutated calreticulin in myeloproliferative neoplasms; $191,645.
2016-2022 Funding from donations by Anne, Victoria and David Norman.
Teaching | Current
- MEDSCI 302 Cancer Biology: Cancer Hallmarks, Cancer Epidemiology, Tumour Microenvironment, Tumour Invasion and Metastasis, Tumour Angiogenesis, Impact of Oncogenes and Tumour Suppressors on Cancer Development and Progression - Clinical Examples, Integration of Morphology, Immunophenotyping and Genetics in Cancer Diagnosis and Research. Course Director.
- MEDSCI 713 Principles of Cancer Therapy: Haematopoietic Stem Cell Transplantation, Cellular Therapies, Modulation of Tumour Microenvironment. Course Coordinator and Director during 2009-2020.
- MEDSCI 714 Advanced Cancer Biology: Lymphoma Biology, Leukaemia Biology. Course Coordinator and Director during 2009-2015.
- Contributes to other MEDSCI and MBChB teaching from stage 2 to 5 (2000-2015).
- 2019-present Mifra Faiz (University of Otago); advisor. Ongoing.
- 2018-present Jixia Li; main supervisor. Ongoing.
- 2015-present James Hearn; main supervisor. Completed.
- 2015-2018 Sarvenaz Taghawi; co-supervisor. Completed.
- 2012-2016 Tania Kamal; main supervisor. Completed.
- 2013-2016 Stacey D'mello; main supervisor. Completed.
- 2012-2016 Alexander Trevarton; advisor. Completed.
- 2010-2015 Thomas Chen; co-supervisor. Completed.
- 2018 Leandro Ladvanszky; main supervisor. Completed.
- 2018 Ahmed Adam; main supervisor. Completed - First Class.
- 2015 Yohanes Nursalim; main supervisor. Completed - First Class.
- 2013 James Hearn; main supervisor. Completed - First Class.
- 2012 Young-Eun Park; main supervisor. Completed - First Class.
- 2012 Sugandha Chugh; main supervisor. Completed - Second Class.
- 2011 Peng (Paul) Sun; main supervisor. Completed - First Class.
- 2010 Thomas Chen; main supervisor. Completed - First Class.
- 2009 Srividya Arunachalam; main supervisor.
- 2006 Supinya Dejnoprat; main supervisor. Completed; First Class.
- 2005 Alexander Trevarton; main supervisor. Completed; First Class
- 2020 Chris Varghese; main supervisor
- 2019 Valery Yizhuo Liu; main supervisor
- 2019 Chris Varghese; main supervisor
- 2017 Ahmed Adam; main supervisor.
- 2015 Filip Nikolic; main supervisor
- 2015 Alyona Oryshchuk; main supervisor.
- 2013 James Hearn; main supervisor
- 2012 Rushi Penumarthy; main supervisor.
- 2011 Caroline Kang; main supervisor.
- 2011 Rushi Penumarthy; main supervisor.
- 2008 Acrane Li; main supervisor.
- 2007 Vincent Chong; main supervisor. Report highly commended by the University of Auckland Judging Panel.
- 2007 Farrah Rodrigues; main supervisor.
- 2006 Isuru Dilshan; main supervisor.
- 2005 Kathryn Goldstone; main supervisor. Report highly commended by the University of Auckland Judging Panel.
- 2004 Alexander Trevarton; main supervisor.
- 2003 Anika Lam; main supervisor.
2019 Invited research visit at the University of Zurich
2017 Invited research visit at the University of Zurich
2016 Invited to the steering group for the International Working Group into Peripheral Glutamate Signalling
2012 Selected into Women in Leadership Programme, University of Auckland
2010 PJ Smith New Zealand Freemasons Travelling Fellowship to the University of Sydney
2010 Visiting Research Fellow, University of Sydney, Australia
2009 McBeath Child Cancer Award, School of Medicine Foundation, University of Auckland
2009 Selected into the Forum of Academic Leaders, University of Auckland
2003 Best Doctoral Thesis Award, University of Auckland
1999 Registrar in Research Award, Royal College of Pathologists of Australasia
1998 Ruth Spencer Medical Research Fellowship, Auckland Medical Research Foundation
1997 Neil Prentice Memorial Prize for the Top Candidate in Pathological Sciences Examination in Australasia
1989 Gold Medal: Best Medical Graduate, Pomeranian Medical School, Poland
1989 Scholarship of the Polish Foundation Talent-Promotion-Progress, Ministry of Health, Poland
- Leads an independent research group into blood and cancer biology
- Works as a specialist haematologist in the Department of Pathology and Laboratory Medicine, LabPlus Haematology, Auckland City Hospital.
- Directs teaching into cancer biology and cancer therapy: MedSci 302 (Cancer Biology; 2009-present), MedSci 713 (Principles of Cancer Therapy; 2009-present) and MedSci 714 (Advanced Cancer Biology - 2009-2015)
- Teaches cancer biology, experimental cancer therapy and clinical haematology in MedSci and MBChB courses
Areas of expertise
- laboratory haematology
- molecular haematology
- leukaemia biology
- megakaryocytes and platelets
- cancer biology
- cancer research
- Faculty Research Development Fund Committee, School of Medical Sciences, Member, 2009-2015; 2018-2019.
- Co-opted member of the Staff Advisory Committee for the School of Medical Sciences, 2013.
International service to:
- CureGRIN Foundation (https://curegrin.org/; Toronto, Canada)
- NCT03247218 clinical trial
- Peripheral Glutamate Signalling Interest Group within the European Calcium Society
- Australasian Leukaemia & Lymphoma Group (ALLG; https://www.allg.org.au/
2015 – present Member, New Zealand Laboratory Haematology Working Group
2012 – present Member, International Society on Thrombosis and Haemostasis (ISTH)
2007 – present Member, American Society of Hematology (ASH)
1998 – present Member, Haematology Society of Australia and New Zealand (HSANZ)
Selected publications and creative works (Research Outputs)
- Hearn, J. I., Green, T. N., Chopra, M., Nursalim, Y. N. S., Ladvanszky, L., Knowlton, N., ... Bohlander, S. K. (2020). N-Methyl-D-Aspartate Receptor Hypofunction in Meg-01 Cells Reveals a Role for Intracellular Calcium Homeostasis in Balancing Megakaryocytic-Erythroid Differentiation. Thrombosis and haemostasis, 120 (4), 671-686. 10.1055/s-0040-1708483
Other University of Auckland co-authors: Cherie Blenkiron, James Hearn, Taryn Green, Dean Singleton, Nicholas Knowlton, Stefan Bohlander, Raewyn Poulsen, Yohanes Nursalim
- Chien, N., Petrasich, M., Chan, G., Theakston, E., Ruskova, A., Eaddy, N., ... Browett, P. J. (2019). Early treatment of acute promyelocytic leukaemia is accurately guided by the PML protein localisation pattern: real-life experience from a tertiary New Zealand centre. Pathology, 51 (4), 412-420. 10.1016/j.pathol.2019.01.003
Other University of Auckland co-authors: Peter Browett
- Kalev-Zylinska, M. L., Hearn, J. I., Rong, J., Zhu, M., Munro, J., Cornish, J., ... Poulsen, R. C. (2018). Altered N-methyl D-aspartate receptor subunit expression causes changes to the circadian clock and cell phenotype in osteoarthritic chondrocytes. Osteoarthritis and cartilage, 26 (11), 1518-1530. 10.1016/j.joca.2018.06.015
Other University of Auckland co-authors: Raewyn Poulsen, James Hearn, Jing Rong, Jacob Munro, Jillian Cornish, Nicola Dalbeth
- Hanna, M. Z., Kalev-Zylinska, M. L., Jackson, S. R., Royle, G., & Blacklock, H. A. (2018). Distinctive features of polycythaemia vera in New Zealand Polynesians. New Zealand Medical Journal, 131 (1482), 38-45. Related URL.
- Kamal, T., Green, T. N., Hearn, J. I., Josefsson, E. C., Morel-Kopp, M. C., Ward, C. M., ... Kalev-Zylinska, M. L. (2018). N-methyl-D-aspartate receptor mediated calcium influx supports in vitro differentiation of normal mouse megakaryocytes but proliferation of leukemic cell lines. Research and Practice in Thrombosis and Haemostasis, 2 (1), 125-138. 10.1002/rth2.12068
Other University of Auckland co-authors: James Hearn, Taryn Green
- Green, T. N., Hamilton, J. R., Morel-Kopp, M.-C., Zheng, Z., Chen, T.-Y. T., Hearn, J. I., ... Barber, P. A. (2017). Inhibition of NMDA receptor function with an anti-GluN1-S2 antibody impairs human platelet function and thrombosis. Platelets, 28 (8), 799-811. 10.1080/09537104.2017.1280149
Other University of Auckland co-authors: Jack Flanagan, Deborah Young, Alan Barber, James Hearn, Taryn Green
- D’mello SAN, Joseph, W. R., Green, T. N., Leung, E. Y., During, M. J., Finlay, G. J., ... Kalev-Zylinska, M. L. (2016). Selected GRIN2A mutations in melanoma cause oncogenic effects that can be modulated by extracellular glutamate. Cell Calcium, 60 (6), 384-395. 10.1016/j.ceca.2016.09.003
Other University of Auckland co-authors: Graeme Finlay, Euphemia Leung, Taryn Green
- Kamal, T., Green, T. N., Morel-Kopp, M. C., Ward, C. M., McGregor, A. L., McGlashan, S. R., ... During, M. J. (2015). Inhibition of glutamate regulated calcium entry into leukemic megakaryoblasts reduces cell proliferation and supports differentiation. Cellular Signalling, 27 (9), 1860-1872. 10.1016/j.cellsig.2015.05.004
Other University of Auckland co-authors: Stefan Bohlander, Sue McGlashan, Peter Browett, Taryn Green
LabPlus Haematology, Auckland District Health Board
Primary office location
M&HS BUILDING 502 - Bldg 502
Level 2, Room 201F
85 PARK RD